Bausch + Lomb confirms its organic growth

Due to strong sales in the second quarter, including better-than-expected organic growth at Bausch + Lomb, Bausch Health raised its adjusted Ebitda guidance for the full financial year. The Canadian group - previously called Valeant Pharmaceuticals - now expects it to be in the range of $3,200 to $3,350 million, ...

Keep reading this article by becoming a member


Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.